lifestyle.pspl.com

Author: Indivior Pharmaceuticals Inc.

Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

May 6, 2026
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

May 5, 2026
Indivior Announces $175 Million Accelerated Share Repurchase

May 5, 2026
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

May 4, 2026
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th

May 4, 2026
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities

May 2, 2026
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

April 30, 2026
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

April 29, 2026
Indivior Announces Proposed Convertible Senior Notes Offering

April 29, 2026
New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

April 29, 2026